evipedia.ai
← Back

Levothyroxine for Health & Longevity

Created on 10/27/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Levothyroxine, a prescription medication that copies the body's main thyroid hormone, replaces missing hormone when the thyroid fails. There it lowers cholesterol and is tied to longer survival than no treatment. With mildly abnormal or normal blood tests, trials found no gain in energy, mood or well-being. No human study shows it slows aging. Main risks come from too much hormone: irregular heart rhythm, bone loss and fractures. (Full Review)

Protocol

Who is treated
TSH >10 mIU/L
European Thyroid Association threshold; a BMJ panel advises against treating TSH <20 mIU/L outside pregnancy
Full replacement dose
1.6 µg/kg/day
Overt hypothyroidism without cardiac disease; older or cardiac start 25–50 µg daily; titration by 12.5–25 µg until TSH normalizes
Time of day
Empty stomach, 30–60 minutes before breakfast
One daily dose; bedtime dosing lowered TSH without quality-of-life change
Time to effect
Peak effect of a dose
4–6 weeks
Changing doses before 6 weeks is a common pitfall
Symptom changes
Several months
Typically, when symptom changes occur

Benefits

Contraindications
  • Uncorrected adrenal insufficiency
  • Euthyroid adults seeking weight loss
  • Euthyroid adults seeking energy or well-being
  • Non-pregnant adults with subclinical hypothyroidism and TSH below 20 mIU/L (possibly not adults ≤30 or with severe symptoms)
  • Adults with already-low TSH (≤0.03 mIU/L) from endogenous or exogenous excess
    •
Key Interactions
  • Calcium carbonate: at least 4 hours apart
  • Iron (ferrous sulfate): 4 hours apart
  • Acid suppressants (omeprazole, pantoprazole, sucralfate, aluminum or magnesium antacids)
  • Binding drugs (cholestyramine, colesevelam, colestipol, sevelamer, lanthanum, orlistat): binders 4 hours apart
  • Oral estrogens (estradiol) and tamoxifen; androgens and anabolic steroids (testosterone, oxandrolone)
  • Enzyme inducers (rifampin, phenobarbital, phenytoin, carbamazepine)
  • Digoxin
  • Insulin and oral antidiabetics (metformin, glipizide)
  • Oral semaglutide
  • Antidepressants (amitriptyline, maprotiline, sertraline)
  • Ketamine
  • Sympathomimetics (pseudoephedrine, phentermine, amphetamines): avoid for weight-loss use
  • Tyrosine kinase inhibitors (imatinib)
  • Conversion blockers (amiodarone, propranolol >160 mg/day, dexamethasone >4 mg/day)
  • Binding displacers (aspirin >2 g/day, furosemide, heparin)
  • Coffee: 60 minutes after the dose
  • Cow's milk
  • Ciprofloxacin
  • Magnesium supplements
  • Chromium picolinate supplements
  • Foods (soybean flour, walnuts, cottonseed meal, dietary fiber, grapefruit juice)
  • Biotin: stopped at least 2 days before testing
    •
Theoretical (inferred from mechanism)
  • Ashwagandha (Withania somnifera)
  • High-dose iodine or kelp
  • "Thyroid support" supplements: avoid
  • Prolonged fasting or very-low-calorie diets
    •

Risk & Side Effects

  • High: Hyperthyroid symptoms at excess doses
    •
  • Medium: Atrial fibrillation, other arrhythmias and angina when over-replaced; higher cardiovascular and all-cause mortality with off-target TSH; fractures and bone loss when over-replaced
    •
  • Low: Life-threatening toxicity when misused for weight loss; adrenal crisis in unrecognized adrenal insufficiency; worsened glucose control in diabetes; loss of a longevity-linked low-thyroid state; hypersensitivity reactions to tablet excipients; seizures at treatment initiation
    •
  • Speculative:

Monitoring

Marker Target Why
TSH 0.04–4.0 mIU/L on replacement Safety check and dose guide
Free T4 0.8–1.8 ng/dL (10–23 pmol/L) Marker levothyroxine raises; safety check for excess
LDL cholesterol No established target for this use; change from own pre-treatment value Falls when deficiency is corrected
Resting ECG and heart rate Resting heart rate 60–100 beats/min; ECG compared with own baseline Safety check for new atrial fibrillation or fast heart rate
Bone mineral density (DXA) No established target; change from own baseline Safety check; loss signals over-replacement
HbA1c (diabetes only) About 4.0–5.6%; in diabetes, change from the pre-start value Safety check on glucose control

Cadence: Baseline TSH and free T4 on two occasions 2–3 months apart; TSH and free T4 6–8 weeks after starting or any dose change, then every 6–12 months once stable, and after product or interacting-drug changes; LDL at 3–6 months; bone density every 2 years in at-risk users; HbA1c about 3 months after starting

Qualitative Assessment

  • Energy and fatigue: improvement expected only when true deficiency is corrected
  • Palpitations or resting heart rate: new racing or irregular beats suggest over-replacement
  • Sleep quality: new insomnia can signal excess dosing
  • Heat or cold intolerance: heat intolerance and sweating suggest excess; cold intolerance suggests too little
  • Weight trend: unexplained loss can reflect excess hormone
  • Mood and anxiety: new nervousness or irritability can reflect over-replacement
  • Bowel habits: constipation suggests too little hormone, diarrhea too much
  • Cognitive clarity: slowed thinking may track deficiency
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.